SPRC (SciSparc) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of scisparc.com (SPRC)

This EV/EBITDA chart for SciSparc Ltd (SPRC), with a value of 0.00, is available below. SciSparc Ltd focuses on independent trials of psychoactive compounds, collaborating exclusively with scientists. The business relies on outsourced synthesis in Europe to avoid plant expenditures. SciSparc Ltd develops drugs to combat Alzheimer's and Tourette's using a method to enhance effects at low doses.

SPRC (SciSparc Ltd.) Company Value to EBITDA history from 11/23/2025 to 11/12/2026

Comprehensive metric breakdowns and analytics for scisparc.com (SPRC)

- market price and analyst price targets:
Price Chart Clearmind Medicine|SPRC - Forecast Levels Chart
- business market valuation indicators:
Market Value SciSparc Corp|SPRC - Company Buyout Price
- book value of equity indicators:
Accounting Value per Share SciSparc|SPRC - Total Stockholders' Equity|Market Capitalization to Book Value Ratio scisparc.com|SPRC - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital SciSparc Ltd|SPRC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity SciSparc|SPRC - Company Cumulative Debt|Debt to Book Capitalization Ratio SciSparc Corp|SPRC - Long-Term Debt Volume|Company Short-Term Debts SciSparc|Quick Ratio scisparc.com
- net income and valuation multiples indicators:
SPRC - Net Financial Result|Expected Profit SciSparc Ltd|SPRC - Business Payback Period|Future Price to Earnings SciSparc Ltd|SPRC - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple SciSparc Corp|SPRC - Operating profit EBITDA|Earnings per share for the last twelve months SciSparc|SPRC - Earnings per share for the trailing year|Quarterly EPS earnings growth scisparc.com|SPRC - Net earnings per share growth this year|Expected earnings per share growth for next year SciSparc Ltd
Initial company analysis:SPRC (Clearmind Medicine)
Product sample of SciSparc

EV/EBITDA determines the total enterprise value, including debt, relative to its operating profit before taxes and amortization. By analyzing the historical EV/EBITDA levels of a company, an investor identifies the balance between the asset's market price and its ability to generate cash flow. For SciSparc Ltd (SPRC), such a valuation confirms the stability of its capitalization, which is supported by the exceptional retention of key scientific staff in the field of neuroscience.

Analysis of competing companies

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alkermes Inc. ALKS|AVDL (Avadel Corp) - Company Value to Operating Income Before Depreciation Ratio|ATAI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ghres.com GHRS|MNMD (MindMed) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA COMPASS Pathways PLC (CMPS)|LBRX (LB Pharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bright Minds Corp (DRUG)|EV/EBITDA Multiple VNDA|CYBN (cybin.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Company Value to EBITDA|CING - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Silo Pharma Inc. SILO|CPHI: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio clearmindmedicine.com|PBM (Psyence Biomedical) - EV/EBITDA Multiple|Seelos Therapeutics Inc. (SEEL) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virpax Pharmaceuticals (VRPX)|Total Company Value to Operating Income Before Depreciation Ratio Karuna Pharma